Wafik S. El-Deiry: Dr. Matt Meyerson speaks at Dana-Farber symposium

Wafik S. El-Deiry posted the following on LinkedIn:

“Dr. Matt Meyerson at Dana-Farber Cancer Institute speaks at 2nd annual translational oncology symposium organized by Sendurai Mani at Legorreta Cancer Center Brown University The Warren Alpert Medical School of Brown University. He discussed progress in lung cancer since 1998 when he started his lab to the present. In 1998 it cost $3B to sequence the genome while now it is approaching $100.

Dr. Meyerson spoke about the incredible team that discovered EGFR mutations, miraculous clinical responses to gefitinib, the path to osimertinib, EGFR mutation and ethnicity, relations between EGFR vs KRAS in lung cancer vs ancestry, NCT05099172 with BAY2927088 (non-covalent EGFR, ERBB2 inhibitor) recently presented at 2024 WCLC and work by Dr. Tao Zou.”

Source: Wafik S. El-Deiry/LinkedIn

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.